Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
77.38(c) 78.15(c) 79.03(c) 79.3(c) 78.6(c) Last
1 072 657 1 178 174 1 062 538 708 889 463 156 Volume
-0.49% +1.00% +1.13% +0.34% -0.88% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 853 M - -
Net income 2021 -87,5 M - -
Net cash position 2021 263 M - -
P/E ratio 2021 -166x
Yield 2021 -
Sales 2022 2 188 M - -
Net income 2022 152 M - -
Net cash position 2022 490 M - -
P/E ratio 2022 88,8x
Yield 2022 -
Capitalization 14 411 M 14 411 M -
EV / Sales 2021 7,63x
EV / Sales 2022 6,36x
Nbr of Employees 3 059
Free-Float 99,4%
More Financials
Company
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of BioMarin Pharmaceutical Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BIOMARIN PHARMACEUTICAL INC.
09/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMa..
PR
09/09SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMa..
PR
09/09WALL STREET STOCK EXCHANGE : A step closer to tapering
09/09ANALYST RECOMMENDATIONS : Boohoo, Boston Beer, Cisco Systems, Eversource, Frontline...
09/09BIOMARIN PHARMACEUTICAL : Stifel Upgrades BioMarin Pharmaceutical to Buy from Hold, Adjust..
MT
09/07Health Care Down As Rally In Sector Pauses -- Health Care Roundup
DJ
09/07PPG Industries, BioMarin fall; AMC, Callaway Golf rise
AQ
09/07Health Care Stocks Falling This Afternoon
MT
09/07Health Care Stocks Flat To Lower Pre-Bell Tuesday
MT
09/07BIOMARIN PHARMACEUTICAL : Health Care
MT
09/07BIOMARIN PHARMACEUTICAL : Says FDA Orders Clinical Hold on Phase 1/2 Gene Therapy Trial in..
MT
09/06BIOMARIN PHARMACEUTICAL : U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 G..
PR
09/06Biomarin Pharmaceutical Inc. Announces U.S. FDA Placed Clinical Hold on BMN 307 Phearle..
CI
08/30BIOMARIN PHARMACEUTICAL : European Commission Approves BioMarin's VOXZOGO (vosoritide) for..
AQ
08/30BIOMARIN PHARMACEUTICAL : Wedbush Lifts Price Target on BioMarin Pharmaceutical to $152 Fr..
MT
More news
News in other languages on BIOMARIN PHARMACEUTICAL INC.
09/07WALL STREET STOCK EXCHANGE : Wall Street sluit overwegend lager
09/07MÄRKTE USA/Wall Street von Gewinnmitnahmen gedrückt - Nasdaq mit Rekord
09/07Les actions du secteur de la santé en baisse cet après-midi
09/07MÄRKTE USA/Gewinnmitnahmen an Wall Street - Nasdaq mit Rekordhoch
09/07BioMarin déclare que la FDA ordonne la suspension clinique de l'essai de thérapie géniq..
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | BMRN | US09061G1013 | MarketScreener
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 78,60 $
Average target price 111,25 $
Spread / Average Target 41,5%
EPS Revisions
Managers and Directors
Jean-Jacques BienaimÚ Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Geoffrey M. Nichol Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIOMARIN PHARMACEUTICAL INC.-10.37%14 411
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336